United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

MAHON PAUL A

A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share. Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders.

LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm

A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement.

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on UTHR's patent for inhaled treprostinil, potentially restricting competition for UTHR's Tyvaso products. However, the stock faces headwinds as consensus EPS estimates were revised 1.4% lower over the past 30 days, and the company is expected to report declining earnings and flat revenue growth.

United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?

USC Pharmacy Alumni ? | Full-Time Investor ?

My posts reflect my personal investment views, not investment recommendations. Always do your own due diligence.

Pharmdca

PM of $PINK Shares for the Cure. Healthcare Hedgefund Manager for past 20 yrs. Scientist, Virologist, Humanitarian, Troglodyte w/a keyboard.

Michael Taylor

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Marty Chargin

Instividual Trader/Investor   https://t.co/6XxJw5gfQN

** INFORMATIONAL PURPOSES ONLY *DO NOT TRADE OFF ANY OF MY INFORMATION**

United Therapeutics Corporation (UTHR) Stock Price, Analysis & Trade Signals